Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00532571 · ClinicalTrials.gov registry record · Phase 2

Effects of Coenzyme Q10 in PSP and CBD

A Phase 2 study of Progressive Supranuclear Palsy and Neurological Disorders, sponsored by Lahey Clinic.

Completed
Registry status
Phase 2
Development phase
1
Study location

NCT00532571 is a Phase 2 study of Progressive Supranuclear Palsy and Neurological Disorders that has completed, run by Lahey Clinic. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00532571, a Phase 2 study of Progressive Supranuclear Palsy and Neurological Disorders, has completed, sponsored by Lahey Clinic.

COMPLETED
Registry status
Phase 2
Development phase
1
Study location

Study Summary

To compare the efficacy, safety and tolerability of Coenzyme Q 10 versus placebo in patients with atypical parkinsonian syndromes corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) ).

Interventions

  • DRUG CoQ10

Study Locations (1)

Massachusetts

  • Lahey Clinic - Burlington

Trial Details

FieldValue
Start Date 2004-01
Est. Completion 2005-09
Phase Phase 2

Sponsor

Lahey Clinic

43 total trials

What the Registry Record Tells You About NCT00532571

The ClinicalTrials.gov registry entry for NCT00532571 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Lahey Clinic, which has 43 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Progressive Supranuclear Palsy appearing as the primary indexed condition, and to 1 intervention - of which CoQ10 is the first listed.

NCT00532571 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00532571 about?

NCT00532571 is a clinical study titled "Effects of Coenzyme Q10 in PSP and CBD". To compare the efficacy, safety and tolerability of Coenzyme Q 10 versus placebo in patients with atypical parkinsonian syndromes corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) ).

What is the current status of trial NCT00532571?

This trial is currently completed. It is a Phase 2 study. The study started on 2004-01. Estimated completion is 2005-09.

What conditions does trial NCT00532571 study?

This clinical trial studies the following conditions: Progressive Supranuclear Palsy, Neurological Disorders.

What interventions are being tested in trial NCT00532571?

The interventions under investigation include: CoQ10 (DRUG).

Who is sponsoring clinical trial NCT00532571?

This trial is sponsored by Lahey Clinic, which has 43 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00532571 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.